The Molecular Pharmacology and Therapeutics Program aims to conceive, design and synthesize new agents for patients with cancer and viral diseases, elucidate their mechanisms of action and resistance, and support preclinical research with these agents in preparation for translational clinical trials. This program has now been headed by Dr. Joseph Bertino for a decade, and encompasses 31 laboratory heads and 51 investigators (including 5 newly recruited investigators), and 36 grants from the NIH or ACS. Its members interact with such basic research areas as natural products chemistry, molecular therapeutics, receptor biology, cell signaling, and transcriptional regulation as well as clinical pharmacology, including neuropharmacology, cytokine therapy and tumor assays. An additional 16 training or career development awards (K01, K05, K07, F32) are held by members of this program. The leadership consists of Dr. Bertino and an executive committee. Researchin- progress is presented at weekly meetings as well as biweekly seminars, weekly journal club, and a monthly drug development meeting, forming a conduit for translation of laboratory research to clinical settings. Members of the program also attend the interdisciplinary group meetings for the major disease areas. Further interaction takes place with the Cornell University Department of Pharmacology, including a joint annual weekend retreat. Dr. Bertino participates in strategic planning and new faculty recruitment in his role as a senior leader in the Department of Medicine. This program makes use of many of the core facilities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-37
Application #
6563639
Study Section
Project Start
2002-01-30
Project End
2002-12-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
37
Fiscal Year
2002
Total Cost
$157,506
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Li, Xiang; Li, Tianfang; Yorke, Ellen et al. (2018) Effects of irregular respiratory motion on the positioning accuracy of moving target with free breathing cone-beam computerized tomography. Int J Med Phys Clin Eng Radiat Oncol 7:173-183
Jain, Devanshi; Puno, M Rhyan; Meydan, Cem et al. (2018) ketu mutant mice uncover an essential meiotic function for the ancient RNA helicase YTHDC2. Elife 7:
Laird, James; Lok, Benjamin; Siu, Chun et al. (2018) Impact of an In Situ Component on Outcome After In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy. Ann Surg Oncol 25:154-163
Leeman, Jonathan E; McBride, Sean M; Spielsinger, Daniel et al. (2018) Head and neck cancers associated with exposure to the September 11, 2001 World Trade Center terrorist attacks. Int J Cancer 142:2485-2490
Reiner, Anne S; Sisti, Julia; John, Esther M et al. (2018) Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol 36:1513-1520
Bhatia, Ankush; Ulaner, Gary; Rampal, Raajit et al. (2018) Single-agent dabrafenib for BRAFV600E-mutated histiocytosis. Haematologica 103:e177-e180
Khalil, Danny N; O'Reilly, Eileen M (2018) Classification of Pancreatic Cancer: Ready for Practical Application? Clin Cancer Res 24:4355-4356
Lau, Colleen M; Sun, Joseph C (2018) The widening spectrum of immunological memory. Curr Opin Immunol 54:42-49
Ebhardt, H Alexander; Root, Alex; Liu, Yansheng et al. (2018) Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer. NPJ Syst Biol Appl 4:26
Munir, Annum; Abdullahu, Leonora; Damha, Masad J et al. (2018) Two-step mechanism and step-arrest mutants of Runella slithyformis NAD+-dependent tRNA 2'-phosphotransferase Tpt1. RNA 24:1144-1157

Showing the most recent 10 out of 8799 publications